Evidence map›Paper›PMID 38910311›Full record

ArticleActa oncologica (Stockholm, Sweden)2024

Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare.

Elisa Bjørgo, Gro L Fagereng, Hege G Russnes, Sigbjørn Smeland, Kjetil Taskén, Åslaug Helland

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elisa BjørgoMATRIX, Norwegian Centre for Clinical Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. elisa@ous-hf.no.
Gro L FagerengInstitute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
Hege G RussnesInstitute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital, Oslo, Norway.
Sigbjørn SmelandInstitute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
Kjetil TaskénInstitute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Åslaug HellandMATRIX, Norwegian Centre for Clinical Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Medical OncologyNeoplasmsPrecision MedicineBiomedical ResearchCongresses as TopicDelivery of Health CareHumansScandinavian and Nordic Countries

Identifiers

PMID38910311
PMCPMC11332496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.